Literature DB >> 22223544

An event-based approach for comparing the performance of methods for prospective medical product monitoring.

Joshua J Gagne1, Alexander M Walker, Robert J Glynn, Jeremy A Rassen, Sebastian Schneeweiss.   

Abstract

BACKGROUND: Prospective medical product monitoring is intended to alert stakeholders about whether and when safety problems are identifiable in longitudinal electronic healthcare data. Little attention has been given to how to compare methods in this setting.
PURPOSE: To explore aspects of prospective monitoring that should be considered when comparing method performance and to develop a metric that explicitly accounts for these considerations.
METHODS: We reviewed existing metrics and propose an event-based approach that classifies exposed outcomes according to whether a prior alert was generated.
RESULTS: In comparing performance of methods for prospective monitoring, three factors must be considered: (1) accuracy in alerting; (2) timeliness of alerting; and (3) the trade-offs between the costs of false negative and false positive alerting. Traditional scenario-based measures of accuracy, such as sensitivity and specificity, which classify only at the end of monitoring, fail to appreciate timeliness of alerting and impose fixed tradeoffs between false positive versus false negative consequences. We provide an expression that summarizes event-based sensitivity (the proportion of exposed events that occur after alerting among all exposed events in scenarios with true safety issues) and event-based specificity (the proportion of exposed events that occur in the absence of alerting among all exposed events in scenarios with no true safety issues) by taking an average weighted by relative costs of false positive and false negative alerting.
CONCLUSIONS: The proposed approach explicitly accounts for accuracy in alerting, timeliness in alerting, and the trade-offs between the costs of false negative and false positive alerting.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22223544      PMCID: PMC3371151          DOI: 10.1002/pds.2347

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  12 in total

1.  Precautions for proactive surveillance.

Authors:  Alexander M Walker; Robert P Wise
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Jan-Feb       Impact factor: 2.890

2.  Comparison of the predicted and observed secondary structure of T4 phage lysozyme.

Authors:  B W Matthews
Journal:  Biochim Biophys Acta       Date:  1975-10-20

3.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

4.  Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project.

Authors:  Preciosa M Coloma; Martijn J Schuemie; Gianluca Trifirò; Rosa Gini; Ron Herings; Julia Hippisley-Cox; Giampiero Mazzaglia; Carlo Giaquinto; Giovanni Corrao; Lars Pedersen; Johan van der Lei; Miriam Sturkenboom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11-08       Impact factor: 2.890

5.  Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD.

Authors:  Martijn J Schuemie
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-10-13       Impact factor: 2.890

Review 6.  Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.

Authors:  Bruce M Psaty; Curt D Furberg; Wayne A Ray; Noel S Weiss
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

7.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

8.  Signal detection for vaccine side effects that have not been specified in advance.

Authors:  Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-03       Impact factor: 2.890

9.  Managing drug-risk information--what to do with all those new numbers.

Authors:  Jerry Avorn; Sebastian Schneeweiss
Journal:  N Engl J Med       Date:  2009-07-27       Impact factor: 91.245

10.  Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices.

Authors:  Frederic S Resnic; Thomas P Gross; Danica Marinac-Dabic; Nilsa Loyo-Berrios; Sharon Donnelly; Sharon-Lise T Normand; Michael E Matheny
Journal:  JAMA       Date:  2010-11-10       Impact factor: 56.272

View more
  4 in total

1.  Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.

Authors:  Joshua J Gagne; Jeremy A Rassen; Alexander M Walker; Robert J Glynn; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2012-03       Impact factor: 4.822

2.  A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.

Authors:  Joshua J Gagne; Shirley V Wang; Jeremy A Rassen; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-04-30       Impact factor: 2.890

3.  Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.

Authors:  Joshua J Gagne; Jeremy A Rassen; Niteesh K Choudhry; Rhonda L Bohn; Amanda R Patrick; Gayathri Sridhar; Gregory W Daniel; Jun Liu; Sebastian Schneeweiss
Journal:  Drug Saf       Date:  2014-03       Impact factor: 5.606

4.  Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system.

Authors:  J J Gagne; R J Glynn; J A Rassen; A M Walker; G W Daniel; G Sridhar; S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2012-05-16       Impact factor: 6.875

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.